A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 92
- Population
- ALL · 50 Years to 85 Years
- Duration
- 2023-06-01 to 2025-12-31
- Intervention
- SGLT2 inhibitor; Glimepiride
- Comparator
- Glimepiride user
- Outcomes measured
- Changes of Cellular senescence markers — Changes from baseline to 3 months after use of SGLT2 inhibitors; Changes of Senescence-associated secretory phenotype — Changes from baseline to 3 months/6 months after use of SGLT2 in…; Changes of biochemistry profiles in blood (10^3/μL) — Changes from baseline to 3 months/6 months after use of SGLT2 inh…; Changes of biochemistry profiles in blood (g/dL) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibi…; Changes of biochemistry profiles in blood (%) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibitors; Changes of biochemistry profiles in blood (mg/dL) — Changes from baseline to 3 months/6 months after use of SGLT2 inhib…; Changes of biochemistry profiles in blood (IU/L) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibi…; Changes of biochemistry profiles in blood (mg/L) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibi…; Changes of biochemistry profiles in blood (μEq/L) — Changes from baseline to 3 months/6 months after use of SGLT2 inhib…; Changes of biochemistry profiles in blood (μU/mL) — Changes from baseline to 3 months/6 months after use of SGLT2 inhib…; Changes of biochemistry profiles in blood (mmol/L) — Changes from baseline to 3 months/6 months after use of SGLT2 inhi…; Changes of body composition using Inbody (kg) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibitors; Changes of body composition using Inbody (cm) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibitors; Changes of body composition using Inbody (cm2) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibito…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Senolytics · 100%Title contains controlled term: cellular senescence. Abstract contains controlled term: cellular senescence. Source terminology contains: cellular senescence. Title supplies longevity context: senescence. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.